Login / Signup

Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections.

David Needham
Published in: AAPS open (2023)
The online version contains supplementary material available at 10.1186/s41120-023-00072-x.
Keyphrases
  • coronavirus disease
  • sars cov
  • social media
  • health information
  • psychometric properties
  • ionic liquid
  • drug administration
  • chronic rhinosinusitis
  • respiratory tract
  • respiratory syndrome coronavirus
  • healthcare